News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zalicus Inc. (ZLCS) Announces Closing Of CHTS Service Business Sale To Horizon Discovery Group



6/2/2014 10:32:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has closed the sale of its combination High Throughput Screening (cHTS) platform and related assets to Horizon Discovery Group for $8 million plus certain additional amounts relating to the working capital of these assets. As a result of the cHTS sales proceeds, the amount of Zalicus’ net cash expected at the closing of the merger with Epirus Biopharmaceutical will be in excess of $9 million.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES